Advertisement
Advertisement
BLTE
Belite Bio, Inc - ADR
173.11
USDSponsored
+0.54
+0.31%
Mar 06, 15:59 UTC -5
Closed
After-Market
174.50
+1.39
+0.80%
BLTE Earnings Reports
Positive Surprise Ratio
BLTE beat 6 of 14 last estimates.
43%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.58
Implied change from Q4 25 (Revenue/ EPS)
--
/+52.63%
Implied change from Q1 25 (Revenue/ EPS)
--
/+28.89%
Belite Bio, Inc - ADR earnings per share and revenue
On Mar 02, 2026, BLTE reported earnings of -0.38 USD per share (EPS) for Q4 25, beating the estimate of -0.55 USD, resulting in a 31.80% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.68% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.58 USD, with revenue projected to reach -- USD, implying an increase of 52.63% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Ocugen, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.06
Surprise
-1.35%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Belite Bio, Inc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Belite Bio, Inc - ADR reported EPS of -$0.38, beating estimates by 31.8%, and revenue of $0.00, 0% as expectations.
How did the market react to Belite Bio, Inc - ADR's Q4 2025 earnings?
The stock price moved down -6.68%, changed from $190.30 before the earnings release to $177.58 the day after.
When is Belite Bio, Inc - ADR expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Belite Bio, Inc - ADR's next earnings report?
Based on 6
analysts, Belite Bio, Inc - ADR is expected to report EPS of -$0.58 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement